

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab)  
Recombinant Antibody  
Catalog # APR10097****Specification**

---

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Product Information**

|                   |                        |
|-------------------|------------------------|
| Application       | FC, E, FTA             |
| Primary Accession | <a href="#">P32970</a> |
| Reactivity        | Human                  |
| Clonality         | Monoclonal             |
| Isotype           | IgG1                   |
| Calculated MW     | 146.1 KDa              |

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Additional Information**

**Target/Specificity**  
TNFSF7 / CD27L / CD70

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Protein Information**

**Name** CD70

**Synonyms** CD27L, CD27LG, TNFSF7

**Function**  
Cytokine which is the ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.

**Cellular Location**


Membrane; Single- pass type II membrane protein

### Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Images




Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) is more than 99.29% ,determined by SEC-HPLC.



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC150=0.06731 µg/mL



The endocytosis ratio vorsetuzumab by 786-O increased with the increase of antibody concentration, and the Internalization Rate (%) reached 55% at antibody concentration of 0.67 nM.